This chapter describes the development of ASAQ, a new fixed-dose combination of artesunate and amodiaquine (which, it is argued, can serve as a model for future drug development to treat neglected diseases); the need for improved antimalarial treatments; the scientific evidence in favour of ASAQ; the public-private partnership for its development and production; activities in registration, marketing, etc. to get it to the patients who need it; and its implications for the development of other needs-driven drugs.
Pécoul, B.; Sevcsik, A.M.; Amuasi, J.; Diap, G.; Kiechel, J.R. The story of ASAQ: the first antimalarial product development partnership success. In: Matlin, S.A.; Francisco, A. de; Sundaram, L.; Faich, H.S.; Gehner, M (Eds). Health Partnerships Review. Global Forum for Health Research, Geneva, Switzerland (2008) 77-83. ISBN 978-2-940401-05-5